Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (28274)	2/18/1999 11:58:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

When LGND screened AGN's retinoids and rexinoids, dozens if not hundreds of interesting compounds were identified. It sounds like additional compounds which interact with PPAR/RXR heterduplexes have also been identified. I suspect that LLY will want to keep much of this under wraps. LLY has Actos to run with for diabetes and they want to grab market share from WLA and SBH. LGND's second (I would call third) generation rexinoids are probably specific for RXRalpha. Targretin (and probably LGD1268 and LGD1324) activate all three RXR subtypes, but only RXRalpha is involved with insulin sensitization through heteroduplex formation with PPARgamma.